Submitted by web@researchtop... on Mon, 06/28/2010 - 17:44
Correlation of BRCA Mutation Status with Responses to Platinum Therapy and PARP Inhibitors in Patients with Ovarian Cancer and Triple-Negative Breast Cancer (TNBC)
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from June 30, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from presentations at ASCO 2010 and transcribed comments from a recent interview with Deborah K Armstong, MD (6/22/10)
Gelmon KA et al. Can we define tumors that will respond to PARP inhibitors? A Phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. Proc ASCO 2010;Abstract 3002.
Konstantinopoulos PA et al. A gene expression profile of BRCAness that correlates with responsiveness to platinum, PARP inhibitors and with outcome in epithelial ovarian cancer. Proc ASCO 2010;Abstract 5004.
Konstantinopoulos PA et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;[Epub ahead of print]. Abstract